Stock Events

Stock Events

Q/C Technologies 

$3.44
67
+$0.05+1.47% Tuesday 04:00

Statistics

Day High
3.44
Day Low
3.39
52W High
-
52W Low
-
Volume
612
Avg. Volume
-
Mkt Cap
14.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-54.32MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QCLS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with MyMD in the development of treatments for viral diseases, inflammatory and fibrotic diseases, which overlaps with MyMD's focus on immune-mediated diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology and oncology sectors, directly challenging MyMD's efforts in developing therapies for immune system diseases and cancer.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm focusing on novel therapies in areas like inflammation, which competes with MyMD's research into immune system modulation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer and immune system disorders, directly competing with MyMD's therapeutic areas.
Merck
MRK
Mkt Cap214.76B
Merck is known for its work in pharmaceuticals and vaccines, including treatments for immune system disorders, making it a competitor to MyMD.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and manufactures drugs and vaccines, including for autoimmune diseases, competing with MyMD's focus on immune system modulation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including immune-mediated diseases, directly competing with MyMD's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on a broad range of healthcare areas, including advanced therapies in immunology and oncology, competing with MyMD.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology and rare diseases but also competes in the broader biopharmaceutical market against companies like MyMD.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases in areas like cystic fibrosis, which involves modulation of the immune system, indirectly competing with MyMD.

About

Q/C Technologies, Inc. is focused on quantum-class photonic computing and blockchain infrastructure. The company has exclusive global rights to LightSolver's light-speed laser processing unit (LPU), a revolutionary light and laser-based computing system aimed at cryptocurrency vertical applications, reducing energy consumption by up to 90% while outperforming traditional GPUs and quantum computers.
Show more...
CEO
ISIN
US62856X3008

Listings

F
DE
DQS.F
XNAS
US
QCLS
BOATS
BOATS
QCLS.BOATS
LSE
GB
0A8D.LSE

0 Comments

Share your thoughts

FAQ

What is Q/C Technologies stock price today?▼
The current price of QCLS.BOATS is $3.44 USD — it has increased by +1.47% in the past 24 hours. Watch Q/C Technologies stock price performance more closely on the chart.
What is Q/C Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Q/C Technologies stocks are traded under the ticker QCLS.BOATS.
What is Q/C Technologies market cap?▼
Today Q/C Technologies has the market capitalization of 14.33M
What is Q/C Technologies revenue for the last year?▼
Q/C Technologies revenue for the last year amounts to 0 USD.
What is Q/C Technologies net income for the last year?▼
QCLS.BOATS net income for the last year is -54.32M USD.
When did Q/C Technologies complete a stock split?▼
Q/C Technologies has not had any recent stock splits.